RPH-104
Sponsors
R-Pharm, R-Pharm International, LLC, R-Pharm Overseas, Inc.
Conditions
AOSDAdult-Onset Still's DiseaseFMFFamilial Mediterranean FeverHealthyIdiopathic Recurrent PericarditisPericarditisRecurrent Pericarditis
Phase 1
Phase 2
Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
CompletedNCT04692766
Start: 2020-02-12End: 2022-03-22Updated: 2022-10-31
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
Active, not recruitingNCT05092776
Start: 2021-04-29End: 2025-10-30Target: 84Updated: 2024-12-06
Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
SuspendedNCT05107934
Start: 2025-12-31End: 2027-10-31Target: 80Updated: 2024-11-15
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
RecruitingNCT05190991
Start: 2021-10-05End: 2029-01-31Target: 60Updated: 2024-12-16
Phase 3
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
WithdrawnNCT05432960
Start: 2023-12-31End: 2025-08-31Updated: 2024-11-15
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Active, not recruitingNCT05673902
Start: 2020-12-11End: 2026-01-31Updated: 2024-11-15